论文部分内容阅读
肝动脉化疗术(TAI)或肝动脉化疗栓塞术(TACE)是目前治疗中晚期原发性肝癌(肝癌)的首选方法,其疗效常以肿瘤大小、甲胎蛋白(AFP)变化及病人生存期来评价。本文检测肝癌患者介入术前后血清中“恶性肿瘤生长因子”(tumor specific growth factory, TSGF)含量,以探讨其应用价值。
Transcatheter arterial chemoembolization (TAI) or transcatheter arterial chemoembolization (TACE) is currently the preferred method for the treatment of advanced primary liver cancer (liver cancer). The efficacy is often based on the size of the tumor, changes in alpha-fetoprotein (AFP), and patient survival. To evaluate. This article examines the content of tumor specific growth factory (TSGF) in serum of patients with hepatocellular carcinoma before and after interventional therapy to explore its application value.